Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Progress Requires Integrating Data And Therapeutics – AACR Report

Executive Summary

As genomic analysis produces ever-increasing amounts of data on cancer biology, continued progress in oncology will require advances in managing and analyzing data and new approaches to clinical trial design to increase efficiency and address development of treatment resistance to molecularly targeted therapies, the American Association for Cancer Research asserts in its annual Cancer Progress report.

You may also be interested in...



FDA's Evolving Position On Next-Gen Sequencing – And Using Data It Produces

Rapid advances in genetic screening technology have prompted an FDA effort to overhaul its approach to diagnostic regulation and to consider ways to make genomic data available to the health system.

Pandora's Basket? Overenthusiasm May Be Side Effect Of Biomarker-Driven Trials

Sponsors stress that basket trials are designed to find signals of activity that will be followed up with randomized, controlled studies, but NEJM editorial wonders if off-label prescribing will circumvent those intentions.

When Illumina Buys Roche: The Dawning Of The Era Of Diagnostics Dominance

With current technology and resources, a well-funded in vitro diagnostics company can create and pursue a strategy of information gathering and informatics application to create medical knowledge, enabling it to assume the risk and manage certain segments of patients. But few if any pharma or diagnostics firms appear poised to take advantage.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel